Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
Journal article published in 2023 by
David A. Qualls 
,
Nicholas Lambert,
Paolo F. Caimi ,
Mwanasha Merrill ,
Priyanka Pullarkat,
Richard C. Godby,
David A. Bond ,
Graham T. Wehmeyer ,
Jason Romancik ,
Behzad Amoozgar,
Lori Leslie,
Loretta J. Nastoupil ,
Jennifer L. Crombie ,
Jeremy S. Abramson ,
Arushi Khurana
and other authors.
,
Nicholas Lambert,
Paolo F. Caimi ,
Mwanasha Merrill ,
Priyanka Pullarkat,
Richard C. Godby,
David A. Bond ,
Graham T. Wehmeyer ,
Jason Romancik ,
Behzad Amoozgar,
Lori Leslie,
Loretta J. Nastoupil ,
Jennifer L. Crombie ,
Jeremy S. Abramson ,
Arushi Khurana
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.